Skip navigation
Skip navigation

Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world

Truong, Jennifer; Shadbolt, Bruce; Ooi, Marie; Chitturi, Shivakumar; Kaye, G; Farrell, Geoffrey; Teoh, Narcissus


Background: Entecavir and tenofovir potently suppress hepatitis B virus (HBV) replication so that serum HBV DNA levels <20 IU/mL can be achieved after 2 years. Despite this, inadequate suppression is reported in >20% of cases for unclear reasons. Aim: We tested whether 4-week viral load (VL) assessment could improve 96-week treatment outcome. Methods: Data on all chronic hepatitis B patients treated with entecavir or tenofovir between 2005 and 2014 were entered prospectively. Full data capture...[Show more]

CollectionsANU Research Publications
Date published: 2017
Type: Journal article
Source: Internal Medicine Journal
DOI: 10.1111/imj.13244


File Description SizeFormat Image
01_Truong_Week_4_viral_load_predicts_2017.pdf491.54 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator